Major haemorrhage related to surgery in patients with type 1 and possible type 1 von Willebrand disease

Summary

Patients with von Willebrand disease (VWD) frequently bleed under a challenge. The aim of our study was to identify predictive markers of perioperative major haemorrhage in type 1 (VWF:RCo = 15–30 IU dl^-1) and possible type 1 (VWF:RCo = 31–49 IU dl^-1)VWD patients. We recorded perioperative bleeding complications previous to diagnosis and laboratory parameters in 311 patients with 498 surgical procedures. The patients were grouped according to the absence (A) or presence (B) of perioperative major haemorrhages. Eighty-one patients (26%) and 87 surgical procedures (17.5%) presented major haemorrhages associated with surgeries. There was no difference between the percentage of type 1 and possible type 1 VWD patients who had major haemorrhages (32.6% and 24.8% respectively; p=ns). No difference in the prevalence of O blood group, age, gender, positive family history and laboratory test results (FVIII and VWF) was observed, independent of the haemorrhagic tendency. Bleeding after tooth extraction was the most frequent clinical feature observed in patients with perioperative major haemorrhages. The bleeding score and the number of bleeding sites (≥3) were not predictors of major haemorrhage associated with surgery. Caesarean section and adenotonsillectomy showed the highest frequency of major haemorrhages (24.6% and 22.3%, respectively). In conclusion, type 1 and possible type 1VWD patients showed similar incidence of perioperative major haemorrhages. Laboratory tests and positive family history did not prove to be effective at predicting major haemorrhages in patients that had either type 1 or possible type 1 VWD. The history of bleeding after tooth extraction could define risk factors of major haemorrhage.

Keywords

Type 1 VWD - surgery - major haemorrhage - laboratory and clinical predictive markers

• References

• 1 Woods AI, Meschengieser SS, Blanco AN. et al. Clinical features and laboratory patterns in a cohort of consecutive Argentinian patients with von Willebrand’s disease. Haematologica 2001; 86: 420-427.
• 2 Tosetto A, Castaman G, Rodeghiero F. Bleeding scores in inherited bleeding disorders: clinical or research tools?. Haemophilia 2008; 14: 415-422.
• 3 Cumming A, Grundy P, Keeney S. et al. An investigation of the von Willebrand factor genotype in UK patients diagnosed to have type 1 von Willebrand disease. Thromb Haemost 2006; 96: 630-641.
• 4 Biron C, Mahieu B, Rochette A. et al. Preoperative screening for von Willebrand disease type 1: low yield and limited ability to predict bleeding. J Lab Clin Med 1999; 134: 605-609.
• 5 Sadler JE. Von Willebrand disease type 1: a diagnosis in search of a disease. Blood 2003; 101: 2089-2093.
• 6 Federici AB, Mannucci PM. Management of inherited von Willebrand disease in 2007. Ann Med 2007; 39: 346-358.
• 7 Nichols WL, Hultin MB, James AH. et al. von Willebrand disease (VWD): evidence-based diagnosis and management guidelines, the National Heart, Lung and Blood Institute (NHLBI) Expert Panel report (USA). Haemophilia 2008; 14: 171-232.
• 8 Nitu-Whalley IC, Lee CA, Griffioen A. et al. Type 1 von Willebrand disease – a clinical retrospective study of the diagnosis, the influence of the ABO blood group and the role of the bleeding history. Br J Haematol 2000; 108: 259-264.
• 9 Sadler JE, Budde U, Eikenboom JCJ. et al. Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand Factor. J Thromb Haemost 2006; 04: 2103-2114.
• 10 Tosetto A, Rodeghiero F, Castaman G. et al. Impact of plasma von Willebrand factor levels in the diagnosis of type 1 von Willebrand disease: results from a multicenter European study (MCMDM-1VWD). J Thromb Haemost 2007; 05: 715-721.
• 11 De Diego JI, Prim MP, Rodriguez E. et al. Von Willebrand disease as cause of unanticipated bleeding following adenotonsillectomy. Int J Pediatr Otorhinolaryngol 1999; 49: 185-188.
• 12 Jiménez-Yuste V, Prim MP, de Diego JI. et al. Otolaryngologic surgery in children with von Willebrand disease. Arch Otolaryngol Head Neck Surg 2002; 128: 1365-1368.
• 13 Allen GC, Armfield DR, Bontempo FA. et al. Adenotonsillectomy in children with von Willebrand disease. Arch Otolaryngol Head Neck Surg 1999; 125: 547-551.
• 14 Nitu-Whalley IC, Griffioen A, Harrington C. et al. Retrospective review of the management of elective surgery with desmopressin and clotting factor concentrates in patients with von Willebrand disease. Am J Hematol 2001; 66: 280-284.
• 15 Ziv O, Ragni MV. Bleeding manifestations in males with von Willebrand disease. Haemophilia 2004; 10: 162-168.
• 16 Manfredi E, van Zaane B, Gerdes VEA. et al. Hypotiroidism and acquired von Willebrand’s syndrome: a systematic review. Haemophilia 2008; 14: 423-433.
• 17 Schulman S, Kearon C. Definition of major bleeding in clinical investigation of antihemostatic medicinal products in non-surgical patients. Scientific and Standardization Committee Communication. J Thromb Haemost 2005; 03: 692-694.
• 18 Janssen CA, Scholten PC, Heintz AP. A simple visual assessment technique to discriminate between men-orrhagia and normal menstrual blood loss. Obstet Gynecol 1995; 85: 977-982.
• 19 Kunicki TJ, Federici AB, Salomon DR. et al. An association of candidate gene haplotypes and bleeding severity in von Willebrand disease (VWD) type 1 pedigrees. Blood 2004; 104: 2359-2367.
• 20 Rodeghiero F. Bleeding score and bleeding questionnaire for the diagnosis of type 1 von Willebrand disease (WWW document). Available at: http://www.med.unc.edu/isth Last accessed December 2005
• 21 Rodeghiero F, Castaman G, Tosetto A. et al. The discriminant power of bleeding history for the diagnosis of type 1 von Willebrand disease: an international, multicenter study. J Thromb Haemost 2005; 03: 2619-2626.
• 22 Proctor RR, Rapaport SI. The partial thromboplastin time with kaolin. A simple screening test for first stage plasma clotting factor defiencies. Am J Clin Pathol 1961; 36: 212-219.
• 23 Taylor LD. The application of the biotin/avidin system to the von Willebrand factor antigen immunoassay. Thromb Haemost 1988; 59: 251-254.
• 24 Macfarlane DE, Stibbe J, Kirby EP. et al. A method for assaying von Willebrand factor (ristocetin cofactor). Thromb Diath Haemorrh 1975; 34: 306-311.
• 25 Tosetto A, Rodeghiero F, Castaman G. et al. A quantitative analysis of bleeding symptoms in type 1 von Willebrand disease: results from a multicenter European study (MCMDM-1 VWD). J Thromb Haemost 2006; 04: 766-773.
• 26 Favro M, Terrone C, Neira D. et al. Major surgery (radical cystectomy with urethrectomy) in a patient with von Willebrand’s disease type 1. Reliability and limits of hemocoagulative tests. Minerva Urol Nefrol 1998; 50: 247-251.
• 27 Collins PW, Cumming AM, Goodeve AC. et al. Type 1 von Willebrand disease: application of emerging data to clinical practice. Haemophilia 2008; 14: 685-696.
• 28 Lethagen S, Hillarp A, Ekholm C. et al. Distribution of von Willebrand factor levels in young women with and without bleeding symptoms: influence of ABO blood group and promoter haplotypes. Thromb Haemost 2008; 99: 1013-1018.
• 29 Quiroga T, Goycoolea M, Panes O. et al. High prevalence of bleeders of unknown cause among patients with inherited mucocutaneous bleeding. A prospective study of 280 patients and 299 controls. Haematologica 2007; 92: 357-365.
• 30 Conti M, Mari D, Conti E. et al. Pregnancy in women with different types of von Willebrand disease. Obstetrics Gynecol 1986; 68: 282-285.
• 31 Manucci PM. How I treat patients with von Willebrand disease. Blood 2001; 97: 1915-1919.
• 32 Silwer J. von Willebrand’s disease in Sweden. Acta Pediatr Scand Suppl 1973; 238: 1-159.